$AIP

Alpern Paul L sold $414K of AIP

Alpern Paul L (VP and General Counsel) sold 11,504 shares of Arteris, Inc. (AIP) at $35.98 ($0.41M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Alpern Paul L
Published Jun 3, 2026, 9:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AIP
Neutral
medium confidence
Mentioned
$AIP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIPNeutralLow
01

Why it matters

Because the plan is pre-arranged, the disclosure is generally lower-signal than unscheduled selling; it mainly updates the record of insider activity.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental information in the article.

03

What to watch

10b5-1 plans can mask true timing; the key is whether this sale size/frequency differs from prior patterns, which the article does not provide.

Relevance 6/10Novelty 2/10Timing: Filed June 3; sale executed June 1 under a 10b5-1 plan.

Background

The article is an SEC Form 4 insider transaction: an officer (VP and General Counsel) sold shares in an open-market transaction under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$AIPNeutralMedium confidence
Context

Arteris GC Paul L Alpern sold $413,969 of AIP shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction would be small unless accompanied by unusual volume or follow-on insider activity.

Evidence & confidence

The filing is a scheduled 10b5-1 sale by an officer, with no accompanying company-specific news (earnings, guidance, deal, litigation) in the article.

Market effects

No clear sector read-through from a single officer 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

If insider selling accelerates across multiple executives or is paired with other negative disclosures, it could become a sentiment overhang despite 10b5-1 structure.

Key entities

  • Arteris, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Paul L. Alpern

    VP and General Counsel who sold 11,504 AIP shares on June 1, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AIPMedAI 8/10

Arteris (AIP) Q2 2026 Earnings Call Transcript

Arteris, Inc. (AIP) reported Q2 2026 revenue of $24.1 million, up 46% year over year. ACV plus royalties were $99.5 million, up 44%, and remaining performance obligation was $135 million, up 36%. Cash and investments rose to $123 million after an at-the-market raise. Full-year 2026 revenue guidance was raised to $95-$98 million.

MedAI 8/10

Arteris Inc. raises FY26 sales guidance to $95-98M range

Arteris Inc. raised its FY2026 revenue guidance to $95.0 million to $98.0 million, up from $91.0 million to $95.0 million previously. The new range is above the $94.578 million analyst consensus estimate, reflecting stronger-than-expected demand for its NoC interconnects and design automation tools, according to the company.

$AIPHighAI 9/10

Arteris, Inc. (AIP): Results of Operations and Financial Condition

Arteris, Inc. (AIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arteris Announces Financial Results for the Second Quarter and Estimated Third Quarter and Updated Full Year 2026 Guidance CAMPBELL, Calif. - August 6, 2026 - Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, to